Immix Biopharma Files 8-K: Corporate Details Updated
Ticker: IMMX · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1873835
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Immix Biopharma filed an 8-K updating corporate info. Check their LA address and phone number.
AI Summary
Immix Biopharma, Inc. filed an 8-K on November 26, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064, and its telephone number is (310) 651-8041. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides updated corporate information for Immix Biopharma, Inc., which is important for investors and stakeholders to have the most current contact and structural details.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain information about significant financial changes, new risks, or material events.
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- November 26, 2025 (date) — Date of report
- 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064 (address) — Principal executive offices
- (310) 651-8041 (phone_number) — Registrant's telephone number
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the exact name of the company filing this report?
The exact name of the company is Immix Biopharma, Inc.
On what date was this Form 8-K report filed?
The report was filed on November 26, 2025.
Where are Immix Biopharma, Inc.'s principal executive offices located?
The principal executive offices are located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064.
What is the telephone number for Immix Biopharma, Inc.?
The registrant's telephone number, including area code, is (310) 651-8041.
In which state was Immix Biopharma, Inc. incorporated?
Immix Biopharma, Inc. was incorporated in Delaware.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-26 17:10:39
Key Financial Figures
- $0.0001 — registered Common Stock, par value of $0.0001 per share IMMX The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex23-1.htm (EX-23.1) — 3KB
- ex23-2.htm (EX-23.2) — 4KB
- 0001493152-25-025182.txt ( ) — 209KB
- immx-20251126.xsd (EX-101.SCH) — 3KB
- immx-20251126_lab.xml (EX-101.LAB) — 33KB
- immx-20251126_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01
Item 8.01 . Item 9.01 Financial (d) Exhibits . Number Description 23.1 Consent of Crowe LLP 23.2 Consent of KMJ Corbin & Company LLP 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Immix Biopharma, Inc. Dated: November 26, 2025 /s/ Ilya Rachman Ilya Rachman, Ph.D., M.D. Chief Executive Officer